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Abstract
Helicobacter pylori is a Gram-negative spiral-shaped bacterium that infects from 30% to 50% of the world’s population 
and it is one of the most important in dyspeptic syndrome causes of gastritis and peptic ulcer. H. pylori is one of 
the most common chronic bacterial infections especially in the development countries because the socioeconomic 
contribute to chronic disease. The infection induces an acute polymorphonuclear infiltration in the gastric mucosa. 
Infection with H. pylori has been epidemiologically linked to some extra digestive conditions, including ischemic 
heart disease, diabetes mellitus (DM), and others. The patients with DM are at risk for H. pylori infection, since they 
have coupled susceptibility of to a wide range of infections as a result of chronic elevation of blood glucose level 
and impairment of immune functions. Chronic inflammation is a risk factor for coronary heart disease, because 
inflammation, vascular injury and thrombosis are considered to cause atherosclerosis. The risk of cardiovascular 
events is associated with increased levels of the acute phase proteins, C-reactive protein (CRP), and pro-
inflammatory cytokines. Interleukin 6 (IL-6), a major pro-inflammatory cytokine is produced in a variety of tissues, 
including activated leukocytes, adipocytes, and endothelial cells. CRP is the principal downstream mediator of the 
acute phase response and is primarily derived through IL-6-dependent hepatic biosynthesis. Tumor necrosis factor-α 
(TNF-α), as an important inflammatory factor, has been shown to play a central role in the pathogenesis of diabetes. 
CRP and IL-6 were determinant of risk for the development of type 2 DM in apparently healthy middle-aged women. 
Since the prevalence of infected persons with H. pylori in Kosovo is high, the aim of this study was the evaluation of 
cytokines (IL1, TNF-α) and CRP in diabetic type 2 patients with positive H. pylori.
Introduction
Helicobacter pylori is one of the most common 
chronic bacterial infections in the world, especially in 
the development countries because the socioeconomic 
status contribute to chronic disease [1], [26]. Infection 
with H. pylori (H. pylori is a Gram-negative bacteria) has 
been epidemiologically linked to some extra digestive 
conditions, including ischemic heart disease, diabetes 
mellitus (DM), neurological disease, gynecological 
disease, ophthalmology, skin, and oral mucosa 
disease, respiratory, ear, nose and throat disease, and 
hematologic disease [2].
The patients with DM are at risk for H. pylori 
infection [3], since they have coupled susceptibility of to 
a wide range of infections because of chronic elevation 
of blood glucose level and impairment of immune 
functions [4].
Chronic inflammation is a risk factor for 
coronary heart disease, because inflammation, 
vascular injury and thrombosis are considered to cause 
atherosclerosis [5], [6], [7], [8]. The risk of cardiovascular 
events is associated with increased levels of the acute 
phase proteins, C-reactive protein (CRP), and pro-
inflammatory cytokines [9].
Interleukin 6 (IL-6), a major pro-inflammatory 
cytokine, is produced in a variety of tissues, including 
activated leukocytes, adipocytes, and endothelial 
cells. CRP is the principal downstream mediator of the 
acute phase response and is primarily derived through 
IL-6-dependent hepatic biosynthesis. Tumor necrosis 
factor-α (TNF-α), as an important inflammatory 
factor, has been shown to play a central role in the 
pathogenesis of diabetes [10].
CRP and IL-6 were determinant of risk for the 
development of type 2 DM in apparently healthy middle-
aged women [11].
Since the prevalence of infected persons with 
H. pylori in Kosovo is high, the aim of this study was the 
evaluation of cytokines (IL-6, and TNF-α) and CRP in 
diabetic type 2 patients with positive H. pylori.
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Methods
Study subject
The study was an observational study 
performed through case–control method in which was 
two identify groups one as a study group and one as a 
control group conducted from January 2017 to January 
2019.
The patients diagnosed with diabetes type 2 
were selected in the Internal Clinics of University Clinical 
Centre of Kosovo, whereas the samples analysis took 
place in the Medical Laboratory “Bioticus” in Kosovo.
The following subjects were excluded from 
this study: Pregnant woman, patients with antibiotic 
treatment or any other medication known to affect the 
inflammatory markers and those with any diagnosed 
systematic disease. The study was performed in 
compliance with human – studies guidelines and all 
participants were informed about the study and the 
nature of procedure was explained.
Detailed analysis
Blood was obtained from each participant 
subject by venipuncture using tubes without 
anticoagulant. After this, the tube was immediately 
transferred for centrifugation at 2000 rpm for 10 min 
and transferred into Eppendorf tubes and stored at 
temperature −20°C.
Serum samples were obtained for the 
determination of H. pylori antibodies, specific 
immunoglobulin G (IgG) antibodies with a specific high 
sensitivity method using the enzyme-linked fluorescent 
assay technique in an automated instrument of the 
Vidas Family a Mini Vidas (bioMerieux, Vitek, France).
For IL-6, TNF –α, and high sensitivity CRP 
(hs-CRP) serum samples were assessed using a kit 
with a specific high sensitivity methodology – ELISA 
test, according to the manufacturer’s instructions (IBL 
International GmbH, Hamburg, Germany).
Statistical analysis
Statistical analysis was analyzed with the 
Vassar-Stats system. T-test was conducted and 
the average, correlation (r) and standard deviation 
were counted. These results are shown in the table 
presentation. The differences in control group and 
study group were compared using the Student’s t-test 
of mean value. The average and standard deviation 
were assessed for IL-6, TNF-α, and hs-CRP. The 
correlation of IL-6, TNF-α, and hs-CRP was compared 
between diabetic patients with H. pylori positive and 
healthy subject. Differences were considered significant 
when p < 0.05.
Results
Eighty participants were enrolled in this study 
aged between 40 and 60 years old both gender.
All participants were divided in two groups. 
The first study group contains 50 patients, 30 male 
and 20 female who were identified as a diabetic 
type 2 patients with regular oral or parenteral therapy 
and also positive H. pylori IgG antibodies and control 
group which contains 30 subjects which were identified 
as healthy subject with no disease.
Control group was healthy subjects without 
any clinical signs related to diabetes and H. pylori.
Mean values in diabetic patients and control 
group are shown in Figure 1. 
Figure 1: The comparison of mean values in patients and control group
Comparisons of inflammatory values in diabetic 
patients with H. pylori positive and control group are 
summarized in Table 1.
Table 1: Inflammatory markers in patients and control groups
Parameters Healthy n=30 Diabetic with H. pylori n = 50 p-value
Age (years, mean±SD) 42.13±1.92 52.22±4.66
Gender n %
Female 14 (47) 20 (40)
Male 16 (53) 30 (60)
Glucose
Mean±SD 4.26±0.47 16.5±5.53
H. pylori IgG
Mean±SD 4.51±1.55 5.12±4.3
IL-6
Mean±SD 3.5±1.1 8.9±14.3 0.02*
TNF-ɑ
Mean±SD 8.68±6.19 12.1±8.7 0.04*
hs-CRP
Mean±SD 0.6±0.5 2.5±2.6 0.001*
*Significant difference (Mann–Whitney test). IL-6: Interleukin 6, TNF-ɑ: Tumor necrosis factor-alpha, 
hs-CRP: High sensitive C-reactive protein, H. pylori: Helicobacter pylori IgG antibodies.
Statistical analysis was shown a significant 
difference of inflammatory cytokines in healthy subject 
and those diabetes patient with H. pylori positive with 
regard to the levels of IL-6 (3.5±1.1 vs. 8.9 ± 14.3, 
respectively, p < 0.02) and TNF-α (8.68 ± 6.19 vs. 12.1 
± 8.7, respectively, p < 0.04.
The mean serum level of hs-CRP was 
significantly higher p < 0.001 in diabetic patient with 
H. pylori than in healthy subject (2.5 ± 2.6 vs. 0.6 ± 0.5).
We found also the correlation and significance 
between parameters in patients and control group 
(Table 2).
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Discussion
H. pylori may have an impact on cardiovascular 
conditions and metabolic syndrome [12], [13], [14]. 
Several studies have evaluated the relation of H. pylori 
infection with coronary artery disease; a study done 
by Kowalski concluded that there is a significant link 
between coronary artery disease and infection with 
H. pylori [15]. A study by Bener et al. [16] suggested 
that there is a significant association between H. pylori 
infection and Type 2 DM and interestingly, this infection 
is significantly higher in diabetic obese patients.
H. pylori infection stimulates the production 
of proinflammatory cytokines [27] potentially mediated 
by elevated inflammatory markers such as reactive 
protein C (CRP) [17], [18], [19] and interleukin (IL)-6. 
Inflammation and activated innate immunity have also 
been implicated in the pathogenesis of diabetes through 
insulin resistance [20], [21]. For example, elevated levels 
of inflammatory cytokines may lead to phosphorylation 
of serine residues on the insulin receptor substrate, 
which prevent its interaction with insulin receptors, 
inhibiting insulin action. Lipopolysaccharides from 
pathogens in the gut, such as H. pylori, have also been 
linked to the activation of toll-like receptors, resulting 
in energy harvesting, fat accumulation and stimulation 
of the innate immune system, and consequent insulin 
resistance [22], [23].
Low socioeconomic status includes chronic 
infections such as infection with H. pylori. Other 
contributor as risk factors are poor diet, smoking and 
physical inactivity are well-known contributors to the 
disparity, but only partially explain the gap in health 
states.
Based in literature H. pylori infection 
caused increase of inflammatory cytokines and 
CRP [17], [18], [19].
The results of some studies have shown 
that there is a higher prevalence of H. pylori infection 
in patients with DM type 2 in comparison to control 
group [6], [8], [16], [24], [25], [26], [27].
Infection with H. pylori was found in the previous 
studies to be correlated with elevated levels of CRP, 
IL-6, and TNF-α which are markers of inflammation 
implicated in insulin resistance and development of 
diabetes [9], [21].
The goals of this investigation were to compare 
the mean levels of TNF-α, IL-6, and hs-CRP in serum 
samples of healthy subjects and diabetic subjects 
seropositive H. pylori. The studied cytokines were found 
to be increased in patient group compared to their levels 
in the healthy subjects. In addition, our study suggests 
that the gastric epithelial cells contribute substantially 
to the pro-inflammatory cytokine response to H. pylori 
infection, either by active cytokine production or by 
uptake of cytokines produced by the lamina propria 
or intraepithelial leukocytes [19]. It is very important 
to emphasize that this is the first study conducted in 
Kosovo estimating serum hs-CRP, IL-6, and TNF-α 
levels in diabetic patients with positive H. pylori and 
healthy persons, to have general information on the 
Kosovo population and connection with inflammatory 
markers.
Conclusion
H. pylori may have an impact on cardiovascular 
conditions and metabolic syndrome potentially mediated 
by elevations in inflammatory markers such as CRP and 
IL-6. Inflammation and activated innate immunity have 
also been implicated in the pathogenesis of diabetes 
through insulin resistance.
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